The Supervisory Board is comprised of independent, non-executive individuals who are charged with supervising and advising Crucell's Management Board.

The members of the Supervisory Board include:

Jan Pieter Oosterveld has served as Chairman of our Supervisory Board since June 2, 2006. He has served as a member of our Supervisory Board since May 2004, and was officially appointed at our AGM on June 3, 2004. He retired from Royal Philips Electronics N.V. on April 1, 2004, after an international career of 32 years. He was responsible for Corporate Strategy, Corporate Alliances and the joint ventures with LGE on CRT and LCD. In the latter responsibility he was the Chairman of the Board of LG.Philips Ltd, which went public in April 2004, and Vice-Chairman of the Board of LG.Philips Displays B.V. He was also CEO of Philips Asia Pacific. He graduated as Mechanical Engineer from the Technical University Eindhoven, the Netherlands, and holds an MBA from the Instituto de Estudios Superiores de la Empresa (IESE) in Barcelona, Spain. He was appointed Professor at IESE in 2003. Mr Oosterveld is a member of the Board of Barco (Kortrijk, Belgium), Atos Origin (Paris, France), Cookson Electronics Group (London, UK) and Continental (Hannover, Germany).

   Expiry of Term — 2008

Arnold Hoevenaars has been attending our Supervisory Board meetings as an observer since July 2004, and was officially appointed to the board at our AGM on June 2, 2005. Mr Hoevenaars is a chartered accountant in the Netherlands, and his previous positions include, among other, Chairman of the Management Board of the Achmea Group, Chairman of the Board of Directors and Chairman/CEO of the Executive Board of Eureko B.V. and member of the Management Board and Chief Financial Officer of Royal Boskalis Westminster N.V.

 Expiry of Term — 2009

Steve Davis has been appointed during the 2008 AGM as a member of our Supervisory Board. Mr. Davis was CEO of Corbis until 2007 and now acts as a senior advisor to the company. He has held positions within the United Nations High Commissioner for Refugees and several refugee resettlement programs. Currently he is a member of the Board of Trustees for PATH, a non-profit organization focused on improving public health in the developing world. He is a member of the Board of Trustees for the Fred Hutchinson Cancer Research Center. He holds a board position in Intrepid Learning Solutions, Seattle Foundation, and PlanetOut Inc.

Mr. Davis holds a Bachelor of Arts from Princeton University, a Master

of Arts from the University of Washington and a Doctorate in Law from Columbia University School of Law.

 Expiry of Term — 2012

Seán Lance has served as a member of our Supervisory Board since January, 2004. Mr Lance is Chairman of Chiron Corporation. He joined Chiron as President and CEO in 1998. From 1985 to 1998 he was with Glaxo Holdings where his last position was group Chief Operating Officer and CEO designate. He is a past President of the International Federation of Pharmaceutical Manufacturers Association. Mr Lance is a chartered company secretary and administrator and he also holds a post-graduate qualification in Advanced Financial Management.

   Expiry of Term — 2011

Phillip M. Satow has been a member of Crucell’s Supervisory Board since its incorporation. He spent 14 years at Pfizer, Inc. (PFE-NYSE) where his last position was Vice President, Pharmaceutical Development, Pfizer Europe. From 1985 to 1997, he was Executive Vice President Marketing at Forest Laboratories, Inc. From 1998 to 1999 he was President of Forest Pharmaceuticals, Executive Vice President of Forest Laboratories Inc. and a member of its board of directors. Mr Satow currently serves on the boards of Forest Laboratories Inc. (FRX), Eyetech Pharmaceuticals Inc. (EYET) and is Chairman and CEO of JDS Pharmaceuticals LLC, a privately held pharmaceutical company. Mr Satow received a Masters in Economics from Georgetown University.

 Expiry of Term — 2009

Dr Wilhelmsson has served as a member of Crucell’s Supervisory Board since May 2003. He was previously the Executive Director of research and development of AstraZeneca PLC from 1999 until July 2002, where he was responsible for AstraZeneca’s global R&D. Dr Wilhelmsson joined Astra in 1985 and held various positions until the company merged with Zeneca in 1999. Prior to Astra, he was a lecturer and researcher at the University of Göteborg in Sweden, where he also completed his medical education and PhD. He currently serves on the boards of a number of biotechnology and start-up companies. Dr Wilhelmsson previously served on the board of AstraZeneca PLC.

• Expiry of Term — 2011